John Houston on partnerships
From 102 - Arvinas' PIONEERING PROTAC Tech to Enhance Cancer Outcomes | Interview with CEO John Houston · · BreakingBiotech
“Since December we signed a deal with Pfizer — a co‑development and co‑commercialization agreement on 471 that will help us execute and accelerate plans for trials and later development.”
On , John Houston, Former CEO at Arvinas, spoke about partnerships during 102 - Arvinas' PIONEERING PROTAC Tech to Enhance Cancer Outcomes | Interview with CEO John Houston on BreakingBiotech.
About John Houston
John Houston, former CEO of Arvinas, discussed the company's progress with its PROTAC protein degradation technology in a 2021 interview. He described how the technology differs from traditional therapies by hijacking the cell's ubiquitin ligase machinery to tag proteins for degradation, with the PROTAC molecule then released to perform multiple rounds. Houston noted that the company's estrogen receptor-targeting asset, ARV-471, showed a best-in-class profile as of mid-December 2021, with an average of 62% degradation and a clinical benefit rate of 42% in a heavily pretreated population. He also mentioned that Arvinas signed a co-development and co-commercialization agreement with Pfizer for ARV-471, which included an upfront payment of $650 million, an equity purchase of $350 million, and milestones of up to $1.4 billion. Houston stated that Arvinas was in a healthy financial position with approximately $1.6 billion in cash and investments, allowing the company to advance its prostate cancer program, ARV-110, independently. He said the company was not actively seeking a partner for that program but could consider one later. Houston also discussed a joint venture with Bayer to form Earth Bio, an agrichem company applying protein degradation technology to plant health. He outlined future plans, including targeting difficult proteins like KRAS and BCL-6 in oncology and exploring tau species in neuroscience, with a goal of nominating a clinical candidate roughly every year.